Ahead of Picoplatin SCLC Data, Poniard Opts for $60M CEFF

Poniard Pharmaceuticals Inc., set to report Phase III data next quarter for its next-generation platinum chemotherapy picoplatin in small-cell lung cancer, is adding some flexibility to its financial position with a $60 million committed equity financing facility. (BioWorld Today)